This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Pfizer’s decision to halt further marketing of Beqvez is further sign of the spa...
Pfizer is pulling further away from the gene therapy field with its decision to ...
The pioneering gene therapy developer will be acquired by investment firms Carly...
The Pfizer CEO at the White House, CDC vaccine efforts, and other crucial biotec...
The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug s...
The PMCPA has turned party pooper, coming down on GSK after learning that a U.K....
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
HHS Secretary Robert F. Kennedy Jr. is preparing to remove committee members who...
HHS Secretary Robert F. Kennedy Jr. is preparing to remove committee members who...
Plus more health news stories you need to read this morning.
After announcing acquisition plans at the beginning of 2025, immunotherapeutics ...
Consolidated 3-year rolling work plan for the Oncology Working Party : January 2...
Infectious Diseases Working Party (IDWP) consolidated 3-year rolling work plan 2...
This week on "The Top Line," we dive into several of the biggest failures in cli...
Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading stateme...
The NIH has lost two distinguished leaders as mass layoffs directed by the Trump...
Bluebird Bio announced it would sell itself and its portfolio of gene therapies ...
Acelyrin had been all set to merge into Alumis—but a surprise offer by Concentra...
A slimmed-down BioMarin started the new year open for business, seeking to lever...
Some see the DOJ filing as a sign the Trump administration is willing to maintai...